Recent investigations have centered on the overlap of GLP|GIP|glucagon receptor agonist therapies and dopaminergic signaling. While GIP stimulators are commonly employed for managing type 2 diabetes mellitus, their unexpected consequences on reward circuits, specifically mediated by dopaminergic pathways, are gaining considerable attention. This re